Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing and staging liver fibrosis.

Increased levels of soluble urokinase-type plasminogen activator receptor (suPAR), particularly a plasma level of over 4.75 ng/ml or 6 ng/nl, have been found to be a predictor of whether a subject with COVID-19 symptoms and/or SARS-CoV-2 infection will require oxygen supplementation.

Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.

Compositions and methods for detecting Mycobacterium tuberculosis (MTB) infection in a patient suspected of being infected with Mycobacterium tuberculosis and for distinguishing between active and latent tuberculosis infection are provided. The methods may also be used to monitor progression of MTB infection or to monitor treatment of MTB infected patients. Changes in the expression level of genes are used to aid in the diagnosis, prognosis and treatment of tuberculosis.

A method for the in vitro or ex vivo assessment of the risk of complications in a patient suspected of having an infection, having a SOFA score of less than two, including measuring the level of expression, in a biological sample obtained from said patient, of at least one expression product of the VEGFR2 gene.

Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and -2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing and staging liver fibrosis.

The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting uPA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.

Non-naturally occurring peptides are provided that act as a Src SH2 domain antagonist of cardiotonic steroids. Pharmaceutical compositions comprising the peptides are also provided along with vectors encoding the peptides. Methods of treating a Src-associated disease and reducing Src activity in a cell are further provided and include administering or contacting a cell with an effective amount of the peptide.

A plurality of anti-UPAR single-domain antibodies are obtained by means of phage display library screening technology. The anti-UPAR single-domain antibody can efficiently bind to UPAR, and has application prospects in the treatment of related diseases.

The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokinase plasminogen activator (uPA), kallikrein-8 (hK8), kallikrein-11 (hK11), or desmoglein-3 (DSG3) in a biological sample of a subject when compared to the same type of sample from a subject or a population of subjects that do not have RRMS; diagnosing that the subject in undergoing relapse if the level of expression of the two or more biomarkers has decreased in the subject; and administering a therapeutically effective amount of treatment for RRMS to the subject.